Biocon and US-based Baxter open research centre in Bangalore

Syngene, a wholly-owned subsidiary of Biocon Ltd and a contract research organisation, and Baxter International Inc, a leading global pharmaceutical company, have established the Baxter Global Research Center (BGRC) at Syngene, in Bangalore.
 
BGRC at Syngene is a part of Baxter’s global strategy of building R&D collaborations with strategic partners. This collaboration will support Baxter in the R&D of medical products and devices to serve patients both in India and around the world.
 
A team of over 100 multidisciplinary Syngene scientists will be based at this dedicated centre in Biocon Park, Bangalore. The Syngene team, working closely with Baxter scientists, will engage in a wide range of R&D activities centred on product and analytical development and preclinical evaluation in parenteral nutrition and renal therapy.
 
Jean-Luc Butel, Corporate Vice President & President - International, Baxter, said, “Baxter is pleased to be part of the opening of this Syngene facility dedicated to providing Baxter with technical and scientific capabilities that will augment our own internal resources. Baxter is committed to helping save and sustain patients’ lives worldwide, and innovation is the driver of success in this area.”
 
Kiran Mazumdar Shaw, Chairperson, Biocon, stated, “Biocon is pleased to partner with Baxter through its research services arm, Syngene. We share a common vision with Baxter, focused on developing pharmaceutical products that advance patient care worldwide and this new research centre will be a significant step towards enabling that objective.”
 
Commenting on the collaboration, Peter Bains, Director, Syngene International Limited, said, “The scale and scope of activities signal the strategic nature of the collaboration and also reflect Syngene’s capabilities to offer broad based complimentary integrated development services. We look forward to working closely with Baxter’s scientists to support advancing their R&D goals.”